CGEM - NASDAQ
Cullinan Therapeutics, Inc.
$14.43
-5.9%Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
At a Glance
Live SnapshotCGEM
Other Expenses
Last Annual Value
0.00
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
Failed to load chart data
Cullinan Therapeutics, Inc. Competitors Analysis of other-expenses
| Company | other-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
No comparison data available We couldn't find other-expenses data for this stock's competitors. | |||||
Cullinan Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your CGEM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.